Eph receptors and ephrins as targets for cancer therapy.
about
Claudin 1 in Breast Cancer: New InsightsSpatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.Overexpression and correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progressionThe Achilles' heel of senescent cells: from transcriptome to senolytic drugs.Promiscuous and specific recognition among ephrins and Eph receptorsNew radiotracers for imaging of vascular targets in angiogenesis-related diseases.Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survivalEphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell.Low EphA7 Expression Correlated with Lymph Node Metastasis and Poor Prognosis of Patients with Esophageal Squamous Cell CarcinomaBiological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.Eph/ephrin signaling in the kidney and lower urinary tract.Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma.Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2.Biochemical and biophysical characterization of four EphB kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles.Localization of juxtacrine factor ephrin-B2 in pituitary stem/progenitor cell niches throughout life.Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.Identification of pleiotropic genetic variants affecting osteoporosis risk in a Korean elderly cohort.EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1.Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis.Regulatory roles of ephrinA5 and its novel signaling pathway in mouse primary granulosa cell apoptosis and proliferation.Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.
P2860
Q26774988-D0337B07-1F46-4947-8E18-745F7242F1D6Q33736905-C87DD597-AADA-465F-A4F4-360D28D09F88Q33744888-E025B654-52E5-49EE-9BA1-EA581BA5C905Q34043405-A553E827-2B8C-402C-AAA0-DCCECD686A03Q34150471-E3DAC5F6-4BD6-432D-BC71-2459FA1CD60FQ34216877-0F238681-FDE2-488D-AE76-7FA22709CD93Q34524860-532A23E0-E0F9-4539-B88D-D810CFF4524CQ35210469-E28E7E3D-D038-47EA-B940-B3B49541282DQ35817738-2689CCCD-7950-4151-8A9A-761A8C3485DEQ36947859-AE8D4AA4-400E-4B49-92BA-30512F08C92EQ37690773-ED28DAA5-5990-41CB-902A-95D5F57406A8Q38209232-6DEEF2DB-A4EE-48D3-BC4A-691EF09F6786Q38214511-AC5983BF-9BF0-4D18-8938-78A8BDFB6FAEQ38258602-ED19495E-15E2-4EC0-BC76-6F309C8B00C0Q38436466-1178FAA5-CE25-4B07-AF28-C78BBA1D706FQ38645374-1C65E14E-1DE5-4C67-9C0B-DE67FB925906Q38778869-0BDC2293-F0B3-4F9C-9396-00D8529FFA35Q38952546-C865FD24-6567-424A-A970-509CE6B05300Q41548523-0F6E014E-FC04-45E0-930B-6AE9AE13B96EQ41722293-B4D5F302-F47A-4547-AF9E-9D544472D4ECQ41954025-90BCF991-F0AA-43FC-9873-8DD4FAB6E84AQ46150489-7EE848A2-E326-4DA0-BBE7-E52880BD745EQ46299094-A6D8F15D-D3CF-4074-8136-3F73E92988FFQ47560513-2BA8B69D-FD38-4973-A095-A2F2400C868FQ47616516-74B082D6-F39A-472C-AA65-CF2A34820639Q50454825-3C040BAB-BE79-4359-8A33-9F847A191377Q52605512-B9BD9823-2DC5-4057-86E5-8F940A5CA21EQ53078264-C739336E-C16C-4311-A1FB-0632AABC2142Q53403455-0671A684-2489-481A-98F2-C790E9A62B8CQ55286883-D30D8FDA-C8FC-4300-9664-22A168AB89C6
P2860
Eph receptors and ephrins as targets for cancer therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Eph receptors and ephrins as targets for cancer therapy.
@ast
Eph receptors and ephrins as targets for cancer therapy.
@en
type
label
Eph receptors and ephrins as targets for cancer therapy.
@ast
Eph receptors and ephrins as targets for cancer therapy.
@en
prefLabel
Eph receptors and ephrins as targets for cancer therapy.
@ast
Eph receptors and ephrins as targets for cancer therapy.
@en
P2093
P2860
P921
P1476
Eph receptors and ephrins as targets for cancer therapy.
@en
P2093
P2860
P304
P356
10.1111/J.1582-4934.2012.01612.X
P577
2012-12-01T00:00:00Z